Piramal Pharma Limited, a global pharmaceuticals and wellness company, has committed to a $90 million investment plan towards expanding two of its U.S. facilities. This move comes in response to ongoing demand from U.S. customers, in support of the trend towards U.S. onshoring of drug supply, and in line with Piramal Pharma’s overall belief in the value and benefits of U.S.-based innovation.

In both cases, Piramal Pharma is making brownfield expansions to existing sites, financed by bank loans and internal accruals.

“Since its inception, Piramal Pharma Ltd has invested $570 million in its U.S. drug development and manufacturing capabilities,” said Peter DeYoung, Chief Executive Officer, Global Pharma. “The U.S. is our largest market, where we currently employ approximately 750 people. Expanding the capacities and offerings in these two plants in the U.S., along with the prior major investments made in our Sellersville, PA drug product facility, and our inhalation anesthesia drug substance and drug product facility in Bethlehem, PA, will support our customers who value our offerings in an onshore setting.”

Lexington, Kentucky Facility

Piramal Pharma’s Lexington, Kentucky, facility specializes in sterile compounding, liquid filling, and lyophilization for sterile injectable drug products. The site’s expansion, which includes 24,000 square feet of manufacturing space and a new laboratory, adds commercial-scale manufacturing that will enable the efficient scale-up of clients’ injectable drug products.

Key additions include a new filling line, two commercial-size lyophilizers, a special capping machine, and an external vial washer. The facility is expected to be completed and online by late 2027.

Riverview, Michigan Site

Piramal Pharma’s Riverview, Michigan site, specializes in the development and manufacturing of active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs). Here, the company is adding a commercial-scale suite specifically for the development and manufacturing of payload-linkers. These high potency APIs are used in the development of antibody-drug conjugates (ADCs) and other bioconjugate drugs. The new payload-linker suite is expected to be operational before the end of 2025.